A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.

Kosei KimuraMitsuhiko IwamotoSatoru TanakaDaigo YamamotoKatsuhide YoshidomeHiroyuki OguraRisa TerasawaNobuki MatsunamiYuko TakahashiToshikatsu NittaTakashi MorimotoHiroya FujiokaKanako KawaguchiKazuhisa Uchiyama

Published in: Cancer chemotherapy and pharmacology (2018)

Eribulin as first- or second-line chemotherapy is effective and has manageable toxicity for patients with HER2-negative MBC.

Keyphrases

phase ii
metastatic breast cancer
patient reported outcomes
clinical trial
open label
double blind
phase iii
locally advanced
placebo controlled
oxidative stress
cross sectional
chemotherapy induced
randomized controlled trial
rectal cancer
radiation therapy